Skip to content

Opening book details…

About this Medicine article

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study by Schmid, P. ;Salgado, R. ;Park, Y.H. ;Muñoz-Couselo, E. ;Kim, S.B. ;Sohn, J. ;Foukakis, T. ;Kuemmel, S. ;Dent, R. ;Yin, L. ;Wang, A. ;Tryfonidis, K. ;Karantza, V. ;Cortés, J. ;Loi, S. is a Medicine article available to read on EtoBox.

It is typically read by researchers, students, and practitioners in Medicine.

Author
Schmid, P. ;Salgado, R. ;Park, Y.H. ;Muñoz-Couselo, E. ;Kim, S.B. ;Sohn, J. ;Foukakis, T. ;Kuemmel, S. ;Dent, R. ;Yin, L. ;Wang, A. ;Tryfonidis, K. ;Karantza, V. ;Cortés, J. ;Loi, S.
Publisher
Oxford University Press; Elsevier BV (ISSN 0923-7534)
Published
2020
Field
Medicine (Health Sciences)

More by Schmid, P. ;Salgado, R. ;Park, Y.H. ;Muñoz-Couselo, E. ;Kim, S.B. ;Sohn, J. ;Foukakis, T. ;Kuemmel, S. ;Dent, R. ;Yin, L. ;Wang, A. ;Tryfonidis, K. ;Karantza, V. ;Cortés, J. ;Loi, S.

Browse all works by Schmid, P. ;Salgado, R. ;Park, Y.H. ;Muñoz-Couselo, E. ;Kim, S.B. ;Sohn, J. ;Foukakis, T. ;Kuemmel, S. ;Dent, R. ;Yin, L. ;Wang, A. ;Tryfonidis, K. ;Karantza, V. ;Cortés, J. ;Loi, S.